Yu Fujiwara, MD
@waraonc23
Call me “Fuji”! Heme/onc fellow @RoswellPark ⬅️ IM @MountSinaiNYC TR/immunotherapy/Ph1/GU/Precision Med/🐶&🎹. Paris/Tokyo/NY. 🇯🇵➡️🇺🇸 日本語: @waraonc23jp
Extremely glad to share our meta-analysis work focusing on the incidence of toxicity from perioperative checkpoint inhibitor therapy with fantastic collaborators!! @thenasheffect @adib_elio @AminNassarMD @ZainAsadEP @ACortelliniMD #SusuZhou #NobuyukiHorita in @TheLancetOncol 1/n
Proud to share @niseto’s (new PI @TheCrick) paper: As a postdoc (@CSHL/@HopkinsMedicine), he found #NETs in necrotic tumors—I shrugged. But he looked closer: NETs block tumor vessel perfusion, causing necrosis, hypoxia, EMT & #Metastasis. nature.com/articles/s4158… @JHU_BDP @Nature
It’s my great honor to write the editorial for the pivotal MATTERHORN study @NEJM @YJanjigianMD @ASCO More global collaboration is needed to further improve outcomes for our patients with gastric/GEJ cancer.@OncoAlert @oncodaily nejm.org/doi/full/10.10…
A novel gut bacterium, Hominenteromicrobium mutabilis YB328, boosts anti‑PD‑1 by activating CD103⁺CD11b⁻ dendritic cells → tumor-targeting CD8⁺ T cells migrate into tumors. Gut microbes could be next-gen immunotherapy adjuvants?@Nature nature.com/articles/s4158…
Check out our paper on microbiome modulation strategies in cancer! ascopubs.org/doi/pdf/10.120… Appreciate @montypal’s mentorship and and amazing @ReginaBarCar for including me!
Hats off to @ReginaBarCar who (w @ZeynepZengin @YaleIMed) put together a beautiful overview of #microbiome modulation for the treatment of #solidtumors in @JCO_ASCO. Citing work from innovative #scientists & #trialists in the field like #Routy, #ElKrief, @derosa__lisa, #Zitvogel,…
First time ever in my life to visit Boston for Kidney Cancer Research Summit #KCRS25. It’s also my first time to attend a conference dedicated for kidney cancer research! Looking forward to learning more about research progress and meeting with good people.
🔍 2pm at #KCRS25: Trials in Progress led by @motzermd - packed w updates you won’t want to miss: @NazliDizman IVORY @KotechaMD ENPP3 x CD3 @BradMcG04 STRIKE @PrafulRavi1 LASER @DrKarieRuncie EXACT @VincentWenxinXu NK cell immune therapy Plenty to discuss!
Exciting to see a partnership between @cityofhope and my medical school @KeioGlobal ! It will definitely facilitate research on tumor immunology and microbiome in cancer. @montypal
We’re honored to welcome world-renowned microbiome expert Kenya Honda, M.D., Ph.D. and his research team, to @cityofhope. In partnership with @KeioGlobal, this global collaboration will advance microbiome science and speed breakthroughs in immune-based therapies.
The FDA-AACR Oncology Educational Fellowship provides early-career scientists and clinicians with an opportunity to learn more about drug development and the regulatory review process from @FDAOncology and AACR experts. Apply by Aug 1: brnw.ch/21wU8KW #AACRSciencePolicy
1/11 Our study on subclonal immune evasion in non-small cell lung cancer has just been published in @Cancer_Cell cell.com/cancer-cell/fu…
Really interesting study showing that a newly found microbiome bacteria YB328 can activate effector T cells via the stimulation CD103+CD11b− conventional DCs, potentially overcoming resistance to PD-1 blockade nature.com/articles/s4158…
Molecular and therapeutic landscape of non-clear cell renal carcinoma doi.org/10.1038/s41585… @DrChoueiri @urotoday @DrRosenbergMSK @BradMcG04 @DrKarineTawagi @DrRanaMcKay @MattGalsky @BhardwajLab @sonpavde @nataliagandur @drgaganprakash @vedangmurthy @paulobergerot…
1/ Thrilled to share our work on Chromophobe RCC (ChRCC) and Renal Oncocytic Neoplasms (RONs) out @JCO_ASCO !!! Incredibly thankful to my mentors @BraunMDPhD @DrChoueiri @VanAllenLab and all co-authors @DanaFarber @BIDMC_IM @Yale @BrighamWomens Link: ascopubs.org/doi/10.1200/JC…
Excited to share our work performed at @theNCI addressing needs of rare hereditary kidney cancer through bench to bedside work Bevacizumab + erlotinib for #HLRCC assoc RCC 📍Response rate 72% 📍mPFS 21.1 mo Thanks to the patients who supported the study! nejm.org/doi/full/10.10…
Congrats to the @theNCI Team on this landmark paper in HLRCC! It sets the SOC in this rare kidney cancer variant. @NEJM @NCICCR_SurgOnc @nciccr_gmb nejm.org/doi/full/10.10…
Pleased to report FGFR2b expression in gastric cancer and relationship with other biomarkers @ESMO_Open @myESMO. The results of bemarituzumab phase 3 studies are awaited.@OncoAlert @oncodaily sciencedirect.com/science/articl…
Honored to announce that I was awarded the AACR J&J CORE fellowship. This grant allows me to learn the process of drug development. Thank you @JNJInnovMed INTO team for the kind welcome and @AACR for this opportunity. I also appreciate support from @RoswellHemOnc @Jacobs_Med_UB
We congratulate Yu Fujiwara, MD, the recipient of the AACR-Johnson & Johnson Clinical Oncology Research (CORE) Training Fellowship. We look forward to following his research progress, and we thank Johnson and Johnson for its partnership on this program.
It’s a privilege to work with colleagues who are immensely motivated, breaking barriers, and yet continues to be humble. Proud to call them friends. @RoswellHemOnc @HemOncFellows @IMG_Oncologists #ASCO2025
Most importantly, I was able to re-confirm the tight and really cool connections among co-fellows at @RoswellHemOnc! We from “Snow City” walked around the conference site, talked about science, foods, work, and life in the Windy City! It’s always best to have good colleagues…!
Most importantly, I was able to re-confirm the tight and really cool connections among co-fellows at @RoswellHemOnc! We from “Snow City” walked around the conference site, talked about science, foods, work, and life in the Windy City! It’s always best to have good colleagues…!
Really glad to meet @KashimaMDPhD from @BraunMDPhD @YaleCancer lab at #ASCO25 Very impressive work utilizing humongous scRNAseq, TCR/BCRseq data to capture the characteristics of myeloid components in mRCC response/resistance to IO-based therapy. #JapanesephysicianscientistsinUS
